Ispecimen vs YD Bio
Ispecimen is the larger business, with $1.9m of revenue in fiscal 2025 against $596,817 for YD Bio (3.2 times as much). YD Bio grew faster (16.9% against -79.2%). Ispecimen kept more of each dollar of sales as profit: a net margin of -543.7% against -1392.6%.
| Latest fiscal year | IspecimenISPC, 2025 | YD BioYDES, 2025 |
|---|---|---|
| Revenue | $1.9m | $596,817 |
| Revenue growth | -79.2% | 16.9% |
| Net income | −$10.5m | −$8.3m |
| Operating margin | -465.4% | -883.3% |
| Net margin | -543.7% | -1392.6% |
| Return on equity | — | — |
| Free cash flow | −$4.2m | −$8.0m |
| Cash | $6.9m | $6.0m |
| Total debt | $0 | $6,764 |
| Debt to equity | 0.0% | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | — | — |
| Market value | $1.3m | $446m |
| Price vs our value range | — | — |
| Moat score | 26 (Weak) | — |
| Insider trades, 12 months | 0 buys, 0 sales | 3 buys, 0 sales |